Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Centers for Disease Control and Prevention | FED |
Not provided
Not provided
Not provided
Not provided
It is hypothesized that implementing plasma CrAg screening in clinics providing routine HIV care will enable identification of Vietnamese adult patients with advanced HIV (CD4 ≤100 cells/μL) who have early cryptococcal disease, enable prompt preemptive treatment with high-dose fluconazole, and improve survival.
This is multicenter prospective cohort evaluation of the implementation of a cryptococcal antigen (CrAg) screening program in Vietnam. HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA) and followed up for 12 months with clinical assessments and the collection of routine and supplemental survey data. Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole. Those with symptoms of CNS disease will be treated according to national guidelines. Survival, retention in care, and other clinical outcomes will be documented for patients who test CrAg-positive and are treated with fluconazole and those who test CrAg-negative.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CrAg(+) and CM(+) | Patients with symptoms of CNS disease will be treated according to Vietnam national guidelines for HIV/AIDS management. |
| |
| CrAg(+) and CM(-) | Patients with CrAg(+) and without CM symptoms will be treated with high-dose fluconazole. The initial dosage of fluconazole will be 900 mg taken each day for 2 weeks. This will be followed by fluconazole 450 mg orally each day for 8 weeks. Finally, maintenance treatment with fluconazole 200mg orally each (2 tablets of 100 mg procured especially for the study) day will continue until CD4 >200 cells/µL for at least 6 months. |
| |
| CrAg negative | Patients with CrAg negative results will be managed as other HIV positive patients according to the national guidelines |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fluconazole | Drug | HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole. |
| Measure | Description | Time Frame |
|---|---|---|
| Six (6) and (12) month all-cause and CM-related mortality among patients who screen CrAg-positive and CrAg-negative | Up to 12 months after recruitment | |
| Proportion of all patients tested for plasma CrAg who have positive results | Up to 12 months after recruitment |
| Measure | Description | Time Frame |
|---|---|---|
| Percent of patients with HIV-related hospitalizations at 6 and 12 months | 12 months after recruitment | |
| Percent of patients with new AIDS-defining OIs/conditions at 6 and 12 months | 12 months after recruitment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Newly registering and ART-naive patients with advanced HIV infection
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nguyen Van Kinh, MD, PhD | National Hospital for Tropical Diseases | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| National Hospital for Tropical Diseases | Hanoi | 00000 | Vietnam |
Please contact PI for any enquiries
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D016919 | Meningitis, Cryptococcal |
| D020314 | Central Nervous System Fungal Infections |
| D002494 | Central Nervous System Infections |
| D016921 | Meningitis, Fungal |
| D000163 | Acquired Immunodeficiency Syndrome |
| ID | Term |
|---|---|
| D009181 | Mycoses |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D003453 | Cryptococcosis |
Not provided
Not provided
| ID | Term |
|---|---|
| D015725 | Fluconazole |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Complete blood samples
|
| Causes of death | 12 months after recruitment |
| Six (6) and (12) month retention among patients who screen CrAg-positive and CrAg-negative | 12 months after recruitment |
| Percentage of patients with CD4≤ 100 cells/μL who are lost to follow-up or have incomplete documentation | 12 months after recruitment |
| % of patients with no documented clinic visit 30, 60, and 90 days after date of the scheduled clinic appointment | 12 months after recruitment |
| D002493 |
| Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008581 | Meningitis |
| D000090862 | Neuroinflammatory Diseases |
| D015658 | HIV Infections |
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D015229 | Sexually Transmitted Diseases, Viral |
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D012897 | Slow Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |